<DOC>
	<DOCNO>NCT01265888</DOCNO>
	<brief_summary>A Phase 2 open label , dose escalation study find minimally maximum effective dose ( dose beyond effect PVR see ) inhale nitric oxide generate GeNOsyl® System compare placebo .</brief_summary>
	<brief_title>Study Subjects With PAH PH Secondary IPF Using Inhaled GeNOsyl .</brief_title>
	<detailed_description>Up 54 subject undergoing RHC plan study , shall include subject meet eligibility criterion classify WHO Group 1 PAH WHO Group 3 IPF-PH . Subjects receive inhale nitric oxide GeNOsyl® System characterize hemodynamic response evaluate safety tolerability . Dose cohorts approximately 5 , 15 , 20 ppm nitric oxide air study . Different dose level achieve vary flow rate drug substance ( 80 ppm NO2 balance air ) deliver subject via nasal cannula . Each subject receive two different dos inhale nitric oxide separate placebo ( medical grade air supplemental oxygen ) washout . Eligible subject assign dose cohort escalate manner receive study drug ( 80 ppm nitric oxide air . )</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<criteria>INCLUSION CRITERIA : PAH PHIPF WHO Functional Class ( equivalent classification ) II IV . Subjects use supplemental oxygen must receive stable course therapy minimum 14 day prior study drug administration . All subject ' oxygen saturation must &gt; = 88 % time treatment Echocardiogram within 6 month baseline show sign clinically significant leave sided heart disease Females childbearing potential negative urine pregnancy test , document surgical sterilization , postmenopausal prior administration investigational product . Females childbearing potential must practice adequate birth control . PAH ( WHO Group 1 ) ONLYInclusion Documented diagnosis WHO Group 1 PAH , ( limited , idiopathic , heritable , drug toxin induce , associate connective tissue disease , portal hypertension , repair congenital heart disease , HIV ) ; document previous RHC hemodynamics consistent PAH , WHO Group 1 Pulmonary Function Testing within 6 month prior screening/enrollment show evidence interstitial lung disease ( TLC &lt; 70 % ) obstructive lung disease ( FEV1/FVC ratio &lt; 50 % ) Receiving stable course approve PAH oral mono therapy minimum 14 day prior treatment period Must 1880 year age PHIPF ( WHO Group 3 ) ONLYInclusion Documented diagnosis probable definite IPF use ATS/ERS criterion Previous transbronchial biopsy , perform , show feature support definitive alternative diagnosis Previous bronchoalveolar lavage , perform , show feature provide alternative diagnosis FVC &gt; = 40 % within 6 month baseline visit Diagnosis PH base hemodynamic requirement Age 4085 . Diagnosis IPF &gt; = 3 month prior study drug administration Diagnosis PH base follow hemodynamic criterion ( PAPm &gt; = 25 mmHg ( rest ) / PCWP LVED &lt; =15 mmHg / PVR &gt; 3 Wood Units ) EXCLUSION CRITERIA : PAH PHIPF Have disease associate pulmonary hypertension ( i.e . Group II , IV V ) . Documented uncontrolled systemic hypertension . Left ventricular ejection fraction ( LVEF ) &lt; 40 % . Have chronic kidney disease stage IV worse , require dialysis . Be receive investigational drug , place investigational device , participate investigational drug study within past 30 day . Have atrial septostomy . Have anemia ongoing condition would interfere interpretation study assessment . Have serious lifethreatening disease condition associate PAH PHIPF ( e.g . malignancy require aggressive chemotherapy , renal dialysis , etc . ) Significant , ongoing alcohol drug abuse , unstable psychiatric status . Receiving inhaled parenteral prostacyclins nonapproved combination approve oral PAH therapy . Pregnant lactating subject PAH ( WHO Group 1 ) ONLYExclusion Have change chronic therapy ( include limit oxygen , different category vasodilator , diuretic , digoxin ) PAH add within 14 day study drug administration . Anticoagulants allow discontinue per institutional standard care . History untreated sleep apnea within three month study drug administration . History hemodynamically significant leftsided heart disease evidence leftsided heart disease . PHIPF ( WHO Group 3 ) ONLYExclusion Diagnosis PH primarily due etiology IPF . FEV/FVC ratio &lt; 60 % document within 6 month baseline visit . Hospitalization acute exacerbation IPF within 30 day baseline visit . Recent active pulmonary upper respiratory tract infection . Receiving approve PAH therapy within 30 day study drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>PAH</keyword>
	<keyword>PH IPF</keyword>
</DOC>